HomeAI · summaries
Storia in 5 fonti
Ozempic Maker Novo Nordisk Raises Outlook but Sales Fall on Tough Comparison, Stock Tanks - Novo Nordisk
Novo Nordisk raises 2026 guidance as Wegovy pill tops 5 million U.S. prescriptions, but stock falls despite higher GLP-1 sales expectations.
Confronto fonti
5 prospettive sulla stessa storiaTimeline cronologica
- ·
cnbc.com
Novo Nordisk shares slide after guidance disappoints investors
Novo Nordisk raised its financial outlook as it tries to catch up with rival Eli Lilly in the booming GLP-1 market.
- ·
investors.com
Novo Dives On A Key Miss As Its Battle With Lilly Heats Up
Novo Nordisk stock plummeted Tuesday after the obesity kingpin unexpectedly released its second-quarter earnings a day early.
